Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy

International Journal of Colorectal Disease

Volumn 29, Issue 4, 2014, Pages 485-491

  Yamamoto, Takayuki ^a   Shiraki, Manabu ^a   Bamba, Takuya ^a   Umegae, Satoru ^a   Matsumoto, Koichi ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Calprotectin; Fecal marker; Lactoferrin; Mesalamine; Ulcerative colitis

Indexed keywords

CALGRANULIN; FECAL CALPROTECTIN; INFLIXIMAB; LACTOFERRIN; MESALAZINE; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; THERAPY EFFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; FECES; FEMALE; HUMANS; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MESALAMINE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; YOUNG ADULT;

EID: 84897469415     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-013-1817-3     Document Type: Article

References (27)

1. Langholz E, Munkholm P, Davidsen M, Binder V (1994) Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107:3-11
2. Leo S, Leandro G, Di Matteo G, Caruso ML, Lorusso D (1989) Ulcerative colitis in remission: is it possible to predict the risk of relapse? Digestion 44:217-221
3. Riley SA, Mani V, Goodman MJ, Lucas S (1990) Why do patients with ulcerative colitis relapse? Gut 31:179-183
4. Levenstein S, Prantera C, Varvo V, Scribano ML, Andreoli A, Luzi C et al (2000) Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 95:1213-1220
5. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A et al (2001) Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120:13-20
6. Bischoff SC, Grabowsky J, Manns MP (1997) Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci 42:394-403
7. Poullis A, Foster R, Mendall MA, Fagerhol MK (2003) Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 18:756-762
8. Voganatsi A, Panyutich A, Miyasaki KT, Murthy RK (2001) Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 70:130-134
9. Roseth AG, Fagerhol MK, Aadland E, Schjønsby H (1992) Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 27:793-798
10. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF et al (1997) Functional and clinical aspects of the myelomonocytic protein calprotectin. J Clin Pathol Mol Pathol 50:113-123
11. Baveye S, Elass E, Mazurier J, Spik G, Legrand D (1999) Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med 37:281-286
12. Baynes RD, Bezwoda WR (1994) Lactoferrin and the inflammatory response. Adv Exp Med Biol 357:133-141
13. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D et al (2003) Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 98:1309-1314
14. Sugi K, Saitoh O, Hirata I, Katsu K (1996) Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 91:927-934
15. Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J et al (2008) Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 6:1218-1224
16. Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U et al (2008) Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 28:1221-1229
17. Sipponen T, Björkesten CG, Färkkilä M, Nuutinen H, Savilahti E, Kolho KL (2010) Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 45:325-331
18. D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L et al (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18:2218-2224
19. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15-22
20. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C et al (2005) Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54:364-368
21. D'Inca R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F et al (2008) Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 103:2007-2014
22. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S (2008) Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 14:669-673
23. Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera C, Vera I, McNicholl AG et al (2009) Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 15:1190-1198
24. García-Sánchez V, Iglesias-Flores E, González R, Gisbert JP, Gallardo-Valverde JM, González-Galilea A et al (2010) Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 4:144-152
25. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F et al (1987) 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1984-1988
26. Brannigan AE, O'Connell PR, Hurley H, O'Neill A, Brady HR, Fitzpatrick JM et al (2000) Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 13:361-366
27. McCarthy DA, Rampton DS, Liu YC (1991) Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86:489-493